Page 36 - Read Online

Sobenin et al. Vessel Plus 2017;1:29-37 Vessel Plus
DOI: 10.20517/2574-1209.2016.12
www.vpjournal.net
Original Article Open Access

Small dense and desialylated low density

lipoprotein in diabetic patients

Igor A. Sobenin , Elena V. Galitsyna , Andrey V. Grechko , Alexander N. Orekhov
2,4
1,2
3,4
5
1 Department of Cardiovascular Pathology, Russian Cardiology Research and Production Complex, 121552 Moscow, Russia.
2 Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia.
3 Department of Genetics, Southern Federal University, 344090 Rostov-on-Don, Russia.
4 Institute for Atherosclerosis Research, Skolkovo Innovative Center, 121609 Moscow, Russia.
5 Federal Scientific Clinical Center for Resuscitation and Rehabilitation, 109240 Moscow, Russia.
Correspondence to: Dr. Igor A. Sobenin, Russian Cardiology Research and Production Complex, 15-a 3-rd Cherepkovskaya Str, 121552 Moscow,
Russia. E-mail: igor.sobenin@gmail.com

How to cite this article: Sobenin IA, Galitsyna EV, Grechko AV, Orekhov AN. Small dense and desialylated low density lipoprotein in diabetic
patients. Vessel Plus 2017;1:29-37.

Dr. Igor A. Sobenin is a Leading Researcher at the Department of Cardiovascular Pathology at Russian Cardiology
Research and Production Complex, Moscow, Russia. He has received his MD in Internal Diseases in 1988, PhD
in Endocrinology in 1991, and DSc in Pathophysiology and Biochemistry in 2006. His research activity is related to
molecular, biochemical and cellular mechanisms of atherosclerosis, including genetic and phenotypic markers of
susceptibility, clinical, epidemiological and population studies in the field of chronic diseases with a special emphasis
on atherosclerosis. He has published more than 140 papers in international peer-reviewed journals indexed by
PubMed, Scopus and Web of Science.

ABSTRACT
Article history: Aim: This study was undertaken to investigate the physicochemical properties of modified low
Received: 26-10-2016 density lipoprotein (LDL) in diabetes. Methods: LDL from 10 type 1 and 10 type 2 diabetic
Accepted: 29-12-2016 patients, as well as LDL from 10 non-diabetic subjects, was subdivided into bound and non-
Published: 31-03-2017 bound fractions by affinity chromatography on Ricinus communis agglutinin-agarose, and
further characterized by sialic acid content, hydrated density, electrophoretic mobility, and
the ability to induce cholesterol deposition in cultured cells. Results: The non-bound LDL
Key words:
Diabetes mellitus, fraction was similar to native LDL from healthy subjects, with respect to its physicochemical
properties, and did not produce intracellular cholesterol accumulation. The bound LDL fraction
atherosclerosis,
low density lipoprotein, was characterized by several alterations differentiating it from non-bound LDL, namely,
significantly lowered sialic acid content (by 35-50%, compared with non-bound LDL),
desialylated LDL, increased electrophoretic mobility (by 40-50%), increased hydrated density (difference in
small dense LDL, modae, 5.6-5.9 mg/mL), and smaller particle size (difference in modae, 3.8-4.9 nm). Bound
electronegative LDL
LDL possessed the ability to induce a 2.1- to 2.7-fold increase in intracellular cholesterol
content. Conclusion: The results showed the presence of a dense, small, more electronegative,
desialylated LDL subfraction in the blood of diabetic patients, which is in vivo modified
atherogenic LDL.

Quick Response Code:
This is an open access article licensed under the terms of Creative Commons Attribution 4.0 International
License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, as long as the original author is credited and the new creations are licensed under the
identical terms.
For reprints contact: service@oaepublish.com

© 2017 OAE Publishing Inc. www.oaepublish.com 29